| Dr Beverly Minolta London, MD | |
|
1701 Curtis Rd, Champaign, IL 61822-9678 | |
| (217) 365-6208 | |
| (217) 326-1234 |
| Full Name | Dr Beverly Minolta London |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 31 Years |
| Location | 1701 Curtis Rd, Champaign, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366426033 | NPI | - | NPPES |
| 252618200 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 036142720 (Illinois) | Primary |
| 207V00000X | Obstetrics & Gynecology | ME0073682 (Florida) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Carle Foundation Hospital | Urbana, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carle Health Care Incorporated | 3577515774 | 808 |
News Archive
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
Squamous cell carcinomas are aggressive malignancies arising from squamous epithelium of various organs, such as esophagus, head and neck, lung and skin. Previous studies demonstrated that two master transcription factors, TP63 and SOX2, effect genomic activation in SCCs.
Researchers at the Swedish medical university Karolinska Institutet have developed a new method for counting molecules.
Women with coronary artery disease who completed a 12-week cardiac rehabilitation program were two-thirds less likely to die compared to those who were not referred to the program.
› Verified 8 days ago
| Entity Name | Carle Health Care Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154653947 PECOS PAC ID: 3577515774 Enrollment ID: O20100513000829 |
News Archive
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
Squamous cell carcinomas are aggressive malignancies arising from squamous epithelium of various organs, such as esophagus, head and neck, lung and skin. Previous studies demonstrated that two master transcription factors, TP63 and SOX2, effect genomic activation in SCCs.
Researchers at the Swedish medical university Karolinska Institutet have developed a new method for counting molecules.
Women with coronary artery disease who completed a 12-week cardiac rehabilitation program were two-thirds less likely to die compared to those who were not referred to the program.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Beverly Minolta London, MD 611 W Park St, Urbana, IL 61801-2529 Ph: (217) 383-6941 | Dr Beverly Minolta London, MD 1701 Curtis Rd, Champaign, IL 61822-9678 Ph: (217) 365-6208 |
News Archive
PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
Squamous cell carcinomas are aggressive malignancies arising from squamous epithelium of various organs, such as esophagus, head and neck, lung and skin. Previous studies demonstrated that two master transcription factors, TP63 and SOX2, effect genomic activation in SCCs.
Researchers at the Swedish medical university Karolinska Institutet have developed a new method for counting molecules.
Women with coronary artery disease who completed a 12-week cardiac rehabilitation program were two-thirds less likely to die compared to those who were not referred to the program.
› Verified 8 days ago
Dr. Jody Rachel Delind, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 W University Ave, Champaign, IL 61820 Phone: 217-366-1255 | |
Dr. Candace D Mcgregor, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 W University Ave, Champaign, IL 61820 Phone: 217-366-1255 Fax: 217-366-6106 | |
Ines O Baquero, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1701 W. Curtis Road, Ob/gyn, Champaign, IL 61822 Phone: 217-365-8208 Fax: 217-326-1234 | |
Dr. Adel Samy Raheb, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 W University Ave Ste 303, Champaign, IL 61820 Phone: 217-366-1255 Fax: 217-429-0108 | |
Marta T Spain, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1701 Curtis Rd, Champaign, IL 61822 Phone: 217-326-1477 Fax: 217-326-1110 | |
Sarah B Young, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 101 W University Ave, Champaign, IL 61820 Phone: 217-366-8107 Fax: 217-366-6106 |